Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma

E.J.M. de Jong, Q.P. Janssen, T.F.A. Simons, M.G. Besselink, B.A. Bonsing, S.A.W. Bouwense, S.M.E. Geurts, M.Y.V. Homs, V.E. de Meijer, V.C.G. Tjan-Heijnen, H.W.M. van Laarhoven, L.B.J. Valkenburg-van Iersel, J.W. Wilmink, L.G. van der Geest, B.G. Koerkamp, J. de Vos-Geelen*, Dutch Pancreatic Canc Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1654-1663
Number of pages10
JournalInternational Journal of Cancer
Volume150
Issue number10
Early online date31 Dec 2021
DOIs
Publication statusPublished - 15 May 2022

Keywords

  • chemotherapy
  • pancreatic cancer
  • survival
  • PHASE-III TRIAL
  • OPEN-LABEL
  • CANCER
  • CHEMOTHERAPY
  • MULTICENTER
  • FOLFIRINOX
  • RESECTION
  • SURVIVAL
  • THERAPY
  • TRENDS

Cite this